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ABSTRACT 
SUNEETHA REDDY ELURU  
REGULATION OF EXPRESSION OF THE M143 PROMOTER OF MOUSE 
CYTOMEGALOVIRUS 
AUGUST 2013 
The objective of this research is to examine the regulation of an essential gene (m143) in 
MCMV that has sequence and functional homology to HCMV genes IRS1/TRS1.  All of 
these prevent the shutdown of protein synthesis that is an antiviral defense. Little is 
known about the regulation of these genes at either the transcriptional or 
posttranscriptional levels. Sequential deletion mutant analysis of the m143 promoter was 
done in the context of an SEAP reporter plasmid. The results indicated that viral proteins 
are required for activation and the presence of repressor-binding sites and activation-
binding sites. EMSA shows that SP1 may be important for the activation. Two important 
viral transcriptional regulators IE1 and IE3, each alone weakly activates the m143 
promoter, but together synergize to efficiently activate this promoter. The absence of 
repression with co-transfection experiments support repression by other viral proteins. 
Such studies may lead to novel treatments for cytomegalovirus infection. 
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CHAPTER I 
 
INTRODUCTION 
 
Herpesviruses 
Herpesviruses belong to the Herpesviridae family and come under the order of 
Herpesvirales (1).  This order has been revised and now includes two new families along 
with Herpesviridae. New families include Alloherpesviridae that consists of bony fish 
and frog viruses, and Malacoherpesviridae that consists of oyster herpesvirus (OsHV1). 
Classification criteria for this family are based on the morphology of the virion, sequence 
similarity, serological relationships and biological characters (1, 2).  The Herpesviridae is 
a large family and consists of more than 100 types of viruses that infect a wide range of 
hosts such as mammals, birds, fish and reptiles (1, 2).  Within the family of Herpesiridae, 
non-human species viruses were renamed after the host genus rather than the subfamily, 
so that it would be easy to manage their rising number (1).  Eight of the herpesviruses 
primarily infect humans; herpes simplex virus types 1 and 2, varicella-zoster virus, 
human cytomegalovirus (HCMV), Epstein-Barr virus, human herpesvirus 6, human 
herpesvirus 7, and Kaposi's sarcoma associated virus. Herpesviruses contain linear 
dsDNA surrounded by an icosahedral capsid that is enclosed by tegument proteins. All of 
this is encased by an envelope, which is composed of a lipid bilayer and glycoproteins. 
All herpesviruses share similar characteristics such as virion structure, remaining latent in 
their host and can reactivate from latency (1, 3).  Both primary and reactivated 
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herpesvirus infections can either be asymptomatic or can result in diseases depending on 
the host’s immune system (2, 4).   The virus that is being addressed in this project is 
murine cytomegalovirus  (MCMV), which is a model system for studying HCMV, which 
will be discussed later. 
Classification. Herpesviridae are classified into three subfamilies based on their 
replication and host range: alpha, beta and gamma herpesvirinae (1, 3, 5).  Alpha 
herpesviruses have a large number of hosts and are the least host species restricted, which 
means that human virus can be used to infect other organisms to study pathogenesis. 
Alpha herpesviruses can reproduce quickly in cell cultures and damage cells within a 
short period of time due to their short replication cycle. Alpha herpesviruses establish 
their latency in neuronal cells. Genera of alpha herpesviruses, with an example of each, 
include: Simplexvirus [herpes simplex virus type 1 (HSV-1)], Varicellovirus [varicella 
zoster virus, (VZV)], the avian Mardivirus [Turkey herpesvirus 1], and lltovirus [Marek 
desease herpesvirus 1(GaHV-1)] (3).  Beta herpesviruses are more host specific than 
alpha herpesviruses and infection is limited to very closely related species. Beta 
herpesviruses spread slowly in cell cultures having a longer replication cycle than alpha 
herpesviruses. Beta herpesviruses also can cause host cell enlargement, for example 
HCMV infections hence the name cytomegalovirus due to cell enlargement. Beta 
herpesviruses establish their latency in a variety of cell types.  Some of the examples of 
the beta herpesviruses include the genera of Cytomegalovirus [human cytomegalovirus, 
(HCMV)] Murinemegalovirus [mouse cytomegalovirus, (MCMV)], Roseolovirus [human 
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herpesvirus-6], and Proboscivirus [elephant endotheliotropic herpesviruses (EEHV)] (1) .  
Gamma herpesviruses also have a very limited host range. Gamma herpes viruses can 
replicate in lymphoblastoid cells and establish latency in lymphocytes.  Examples of the 
gamma herpesviruses genera include Lymphocryptovirus [Epstein Barr virus (EBV)], 
Rhadinovirus [murine herpes virus-68 (MuHV4)], Macavirus [Porcine lymphotropic 
herpesvirus 1(SuHV3)] and Percavirus [Equine herpesvirus 2 (EHV2)] (1, 3). 
Cytomegalovirus (CMV) 
Cytomegalovirus causes cell enlargement, this was first called cytomegalia in 
1921 (6).  Cytopathic effect (CPE) can be noticed when cells are infected with CMV with 
characteristic nuclear and cytoplasmic inclusions and cell rounding in many cell types. 
HCMV infects 40%-90% of adults worldwide (7) and infects a large majority of the 
population almost 60% of adults in USA (8).  CMV spreads through bodily secretions 
such as saliva, breast milk, urine and semen (9-11). 
Transmission and pathogenesis of CMV. The seroprevalance of CMV infection 
is inversely related to socioeconomic conditions (11, 12).  Transmission of this virus 
occurs in many ways such as transfer across the placenta from mother to fetus and via 
many body fluids such as mentioned above (9-11, 13).  CMV infection can also occur 
through transplanted organs and blood transfusion (14).  HCMV infection is generally 
asymptomatic but it can sometimes cause infectious mononucleosis in immune-
competent individuals (7).  HCMV causes serious problems in immuno-compromised 
individuals such as AIDS, cancer, and transplant patients either by reactivation from 
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latency or by primary infection as reviewed in (10, 15).  Studies show that immuno-
compromised patients can develop a multisystem disease that might be life threatening as 
reviewed by (16).  For example, retinitis and pulmonary disease are some of the diseases 
that occur in HIV-AIDS patients (17).  HCMV is one of the major causes of birth defects. 
In congenital infections this virus can cause severe damage to the central nervous system. 
The neonates will sometimes have permanent disabilities such as hearing loss or severe 
neurological disorders and also may have signs of enlarged liver and inflammation in the 
lung tissues (18).  CMV has also been implicated in atherosclerosis (19-21).  CMV can 
infect many types of cells such as: epithelial, endothelial, fibroblast cells, monocytes, 
macrophages, hepatocytes and neurons (22, 23).  Understanding the important factors that 
are involved in CMV infection that can affect the pathogenesis, inflammation or immune 
response would help in developing additional therapeutic methods along with currently 
available antiviral drugs.  
Antiviral therapy for CMV infections. There are some antiviral drugs available 
for treating CMV infections such as acyclovir, gancyclovir, valgancyclovir, cidofovir and 
foscarnet. Acyclovir is a 2’-deoxyguanosine analogue and is phosphorylated by host 
kinases to inhibit the viral DNA polymerase at multiple steps (24, 25).  Acyclovir is very 
effective against several herpesviruses but only moderately effective against CMV.  The 
related drug gancyclovir (GCV) is a nucleoside analogue of 2’-deoxyguanosine and it is 
phosphorylated into gancyclovir triphosphate by viral protein kinase, UL97 (26).  
Gancyclovir triphosphates incorporate by competing with dGTPs and inhibit the DNA 
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synthesis by cellular and viral DNA polymerases (27). This drug is commonly used for 
CMV retinitis, CMV pneumonitis, and CMV neurologic disease in AIDS patients. 
However mutations in either viral polymerase or UL97 kinase help CMV to develop 
resistance to gancyclovir (27).  Valgancyclovir is a prodrug of ganciclovir, which was 
developed to supplant intravenous gancyclovir, because oral valgancyclovir achieves 
blood levels comparable with intravenous gancyclovir (28), in addition, CMV is less 
likely to develop resistance against valgancyclovir (28, 29). Valgancyclovir is used in 
solid organ transplant patients and HIV-associated CMV retinitis patients (30).  Potential 
side effects of these drugs include nephrotoxicity and hematologic toxicity, notably 
neutropenia, and thrombocytopenia. It is recommended that the dose of these drugs 
should be reduced if toxicity occurs (31).  Cidofovir is a nucleotide phosphate analogue, 
which is converted into an active diphosphoryl form of cidofovir diphosphate by host 
kinases, this will competitively inhibit viral DNA polymerase (25, 32).  It is mainly used 
in the treatment of CMV retinitis in patients with AIDS (33). Foscarnet is used in patients 
who are failing GCV therapy due to dose limiting factors or viral resistance (34).  
Foscarnet is a pyrophosphonate analogue and it binds to pyrophosphate binding sites to 
block the cleavage of pyrophosphate from the terminal nucleoside triphosphate that is 
being added to the growing DNA chain and thus inhibit viral DNA polymerase activity 
(34).  One of the common side effects of this drug is nephrotoxicity (34).  All of these 
drugs have potential mutagenic effects. They have also been reported to inhibit 
spermatogenesis and hence new therapeutic targets are desirable (35). 
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 Vaccine development. Currently, there is no effective therapy for pregnant 
women when they get primary infection due to CMV, because these drugs can’t be given 
to pregnant women due to their potential mutagenicity (8, 35).  It has been reported that 
congenital CMV diseases affect thousands of newborn children every year (8).  CMV can 
cross the placenta during pregnancy and can be transferred to the fetus. This can cause 
neurological damage to the newborn. Hence it is desirable to develop a vaccine against 
CMV infections (36). However it is challenging to develop a vaccine against CMV due to 
its latency and potential reactivation and so live vaccines might be hazardous. An 
additional challenge is that CMV has developed multiple mechanisms to modify the 
immune response (37). Currently there are several vaccines that are being tested in 
humans. These include live attenuated vaccines and sub unit vaccines encoding 
glycoprotein gB (36, 37). 
CMV Virion structure. All members of the Herpesviridae family share similar 
virion structures, which is used to classify the virus as a family member (1).  The virions 
can vary in size ranging from 120-260 nm depending on the composition of the tegument 
and the morphology of the envelope. CMV is around 200 nm across. Virions consist of 
basically four components those include core, capsid, tegument and envelope shown in 
Figure 1 (38).  The viral core contains a single linear double stranded DNA genome, 
which ranges in size from 120-230 kb depending on the virus, and is arranged around the 
protein core in the form of a torus (38).  CMV has the largest genome of the 
herpesviruses. The CMV genome is predicted to encode approximately 200 genes (39, 
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40).  A protein shell called the capsid surrounds this nucleic acid (dsDNA) and together 
this makes the nucleocapsid. Herpesvirus capsids are icosahedral-structured component 
contains 162 capsomeres and are 100 nm in size (41).  Capsomeres are made with 5 
capsid proteins, major capsid proteins (MCP), TR11, TR12, smallest capsid proteins 
(SCP) and PORT (10).  The capsid is surrounded by an ordered structure called the 
tegument.  Tegument contains several proteins and varies in thickness. The tegument 
proteins help the virus in virion assembly and establishing a productive infection in a new 
cell. During infection they interfere with host functions to overcome the host defense 
mechanisms, and help activate viral gene expression (42).  The final component of the 
herpes virus virion is the envelope, which contains several viral glycoproteins; gB, gH, 
gL, gM, gN, gO and its lipid bilayer membrane is derived from the host cell endoplasmic 
reticulum (ER) membrane (41, 43). 
    
 
 
 
FIG. 1. CMV Virion Structure. The components shown are A, capsid; B, 
glycoproteins; C, tegument; D, DNA core; E, envelope. 
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CMV Replication. Replication starts with viral attachment to the cell surface and 
penetration into the cell (44).  When the virus attaches to the cell, the virus interacts with 
proteoglycan complexes on the cell surface via the virus-encoded glycoprotein complex 
gM:gN. CMV then binds to more specific receptors, for example epithelial growth factor 
receptor (EGFR), through other virus-encoded glycoproteins such as gB (45-47).  Other 
co-receptors to mediate entry must be present on cells that don’t express EGFR. A recent 
study indicates that integrins can be involved in the attachment via highly conserved 
disintgrin-like domains in viral glycoproteins (48).  The gB in the envelope of the virus 
facilitate the fusion with the plasma membrane, depositing the tegument and 
nucleocapsid in the cell cytoplasm. This fusion differs between cell types, fusion in 
endothelial cells requires endocytosis and low pH (49).  After release into the cell, viral 
nucleocapsids migrate to the nucleus via microtubules. The viral genome gets into the 
nucleus through the nuclear pores, where the linear genome circularizes as an episome 
(10).  Gene expression, replication of the CMV genome and assembly of new capsids 
take place in the nucleus. Replication times for HCMV is about 72 hours and for MCMV 
is about 24 hours in fibroblasts. These are the cells generally used in the laboratory. Most 
herpes virus’s gene expression is temporally regulated (4).  There are three phases of 
expression, first, the immediate-early (IE) phase during which necessary transcription 
factors start being made. Secondly, the early (E) phase during which proteins required for 
DNA replication is made.  Thirdly, the late (L) phase during which structural components 
of the virions are made (10).  As mentioned, early gene expression is required for viral 
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genome replication to take place. DNA synthesis occurs by a “rolling-circle” method. 
According to this model, the replication of a single circular DNA occurs in a 
unidirectional way, which results in several copies of the viral genome connected end to 
end, called concatemers (10).  The DNA has to be cleaved for the genome to be packaged 
into capsids. Capsid proteins are transported into the nucleus and form capsomers 
surrounding scaffolding proteins. These are assembled into pro capsids. Cleavage of the 
genome is concurrent with entry into the capsid. Viral DNA gets into the capsid via portal 
proteins, the scaffolding proteins get out and portal gets closed (10).  The details of this 
process are still not well understood. Tegument proteins are added in an ordered sequence 
and some are added in the nucleus, which facilitates nuclear egress, while some are added 
in the cytoplasm for final egress (10).  The nucleocapsid egresses by budding. According 
to the “double envelope theory”, capsid attains an envelope by leaving the nucleoplasm 
through the inner nuclear membrane, which will then be lost by fusion with the outer 
nuclear membrane releasing the nucleocapsid into the cytoplasm (50).  Then the final 
envelopment occurs at Golgi derived vesicles (10, 51, 52).  The enveloped virus is then 
transported via cellular vesicular release mechanisms to the cell membrane. There the 
virion is released by vesicular fusion with the cell membrane (4, 10). 
(i) Gene classes. The focus of this study is gene regulation, hence HCMV gene 
class are being discussed a little more here. CMV genes are temporally regulated and 
classified in to three kinetic classes depending on the time and sensitivity to different 
inhibitors. They are immediate early genes (IE), early genes (E) and late genes (L) (10, 
  
10  
53) .  Immediate early genes are independent of any newly synthesized viral proteins and 
mRNA is made in the presence of protein synthesis inhibitors. The timing discussed here 
will refer to the kinetics of MCMV.  During immediate early times, within the first 4 
hours post infection (hpi), regulatory proteins are expressed including some which act as 
transactivators for expression of viral early and late proteins along with cellular proteins. 
IE1/IE2 are extensively studied immediate early transcriptional regulators in HCMV and 
IE1/IE3, are the homologues in MCMV (10, 54).  IE1/IE3 are under the control of the 
major immediate early promoter (MIEP) and are splice variants. This gene region has 
five exons and two alternative polyadenylation signals. Exons 1, 2, 3 and 4 encode IE1 
transcript and exons 1, 2, 3 and 5 encode IE2 transcript (IE3 of MCMV) (54, 55). 
However there are other transcriptional regulators that are expressed in all kinetic classes 
of gene expression.  Expression of early genes requires the presence of functional IE 
products. During early times, starting around 4 hpi, proteins that are involved in DNA 
replication is expressed (10).  Late genes are expressed after the onset of DNA replication 
starting around 12 hpi. Late proteins can be distinguished from early genes using DNA 
synthesis inhibitor such as phosphonoformic acid (PFA, foscarnet), which prevent viral 
DNA replication (10, 53).  During late times structural proteins necessary for viral 
assembly get expressed (10).  
Latency. When a herpes virus infects its hosts, this infection can either lead to a 
lytic infection in which the virus replicates and causes cell death or latent infection in 
which the virus stays dormant in the host. Latency is defined as the presence of viral 
  
11  
DNA but no infectious virus production (56).  Histone modifications play an important 
role in the repression of gene expression. Acetylated H3 was found in HCMV lytic 
infections and dimethylated H3 causes repression of HCMV genes in latency (57).  An 
additional mechanism is down regulation of immediate early gene expression.  CCAAT 
displacement protein (CDP or CUX1), a cellular protein, binds to a CUX1 site in the 
major immediate early promoter (MIEP) and represses MIEP expression (58).  Latency in 
CMV can be in several cell types. These include bone marrow and peripheral blood (59, 
60).  It has been shown that bone marrow precursors are a key site of latency for HCMV 
persistence and reactivation; peripheral blood monocytes circulate the virus, and 
differentiation of latently infected monocytes into macrophages leads to reactivation and 
productive infection (60).  A study reported on latency in MCMV showed that during 
latency high copy numbers of DNA were present in lung tissue and could be reactivated 
(61).  
Genome characteristics. MCMV contains a 230 kb genome that encodes for 
around 170 genes and HCMV contains a 229 kb genome that encodes for about 170 
genes (39, 40).  Herpesvirus’s genomes consist of one or two unique sequences flanked 
by repeated sequences (62).  The HCMV genome consists of two covalently linked 
segments: the unique long and unique short (UL and US) regions, flanked by two sets of 
inverted repeats TRL/IRL and TRS/IRS (Figure 2).  The HCMV open reading frames 
(ORFs) are numbered sequentially and designated by their location within the unique or 
repeated regions of the viral genome (39, 63).  For example US22 is the 22nd ORF located 
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in the unique short (US) region.  The genomes of other β−herpesviruses are linear and 
lack internal repeats. The MCMV genome consists of a single unique sequence with short 
direct repeats at either end (64). MCMV’s ORF’s are designated based on location within 
the genome. In addition, ‘m’ is for mouse. Homologs to HCMV ORFs are designated 
with upper case letters (M112/M113 for IE1/IE3 gene region), those with sequence 
similarity below a certain level (exact percentage is not clearly stated in the original 
paper) are designated with lower case letters (m22) (40). 
 
 
 
 
 MCMV as a model for HCMV. MCMV and HCMV share similarities in 
pathogenesis and genome organization. Both can cause diseases either by reactivation 
from latency or by primary infection and can establish a lifelong latency (10).  Hence 
MCMV is useful to study conserved genes. There are several families of related open 
FIG. 2. HCMV and MCMV genome structures with relative locations of US22 gene 
family members. TRL; Terminal repeat long, TRS; Terminal repeat short, IRL; Internal 
repeat long, IRS; Internal repeat short. 
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reading frames among the conserved genes, resulting from gene duplication events. One 
of these gene families is the US22 gene family (10, 39, 40).  US22 family members are 
characterized by the presence of at least one of four conserved sequence motifs and are 
specific to the beta herpesviruses.  Motifs I and II are well defined and contain short 
stretches of hydrophobic and charged residues. Motifs III and IV are less well defined 
and contain stretches of nonpolar residues (39, 40).  The US22 gene family consists of 12 
members in each HCMV and MCMV(40). The closest homologue for each HCMV US22 
family member is not another HCMV gene but the MCMV gene with similar location in 
the genome (Figure 2).  This project addresses one of the US22 genes, m143, which is 
essential for viral replication. MCMV’s m143 and its neighbor m142 are 3’–coterminal 
transcripts and are the closest homologues of IRS/TRS1 in HCMV, which inhibit the 
same antiviral response (65, 66).  They also exhibit similarities in expression kinetics 
(67-69).  When the cell is infected, cellular antiviral defense mechanisms are activated, 
such as the protein kinase R (PKR) pathway.  PKR binds to dsRNA produced by the 
virus and becomes auto-phosphorylated, activating PKR.  Activated PKR phosphorylates 
the translation initiation factor eIF2α leading to the shutdown of global protein synthesis.  
The protein m143 forms a complex with m142, which binds to dsRNA and PKR to 
inhibit the PKR antiviral pathway (70, 71).  Because m143 is essential for virus 
replication, it is important to determine how this gene is regulated. 
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Promoter regulation 
Gene expression can be regulated at various steps, such as polyadenylation (72), 
splicing (73), mRNA stability (74), chromatin remodeling (75), transcription initiation 
(76) etc.   Regulation of transcription initiation is an essential step in determining whether 
a gene is expressed or not in a cell, which consequently results in the making of mRNA 
and protein.  Transcriptional initiation is regulated by the binding of certain proteins to 
the sequences in a promoter.  A eukaryotic promoter contains protein-binding sites for 
various transcription factors (TFs), which regulate the promoter (77).  Hence, promoter 
analysis is important to identify the functional transcription binding sites.  A TATA 
binding site is generally located 20-25 bases upstream of the transcriptional start site. 
This is called as core promoter where the RNA polymerase II binds with the help of other 
transcription factors.  TATA binding protein (TBP) binds to TATA binding sequence. 
Transcription factor IID (TFIID) binds to TBP, this leads to the binding of RNA 
polymerase II along with five other transcription factors and forms a pre-transcription 
initiation complex (77).  In promoters without the consensus TATA box, usually TBP 
binds to the promoter and TFIID complex requirements are similar to promoters with 
consensus TATA box (78).  
Herpesviruses replicate inside the nucleus and they largely utilize the host cell’s 
transcription machinery and DNA repair system for successful infection (3). 
Transcription is an important step for any genes expression.  In herpesviruses cellular 
factors and chromatin remodeling complexes play an important role in lytic and latent 
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infections.  Host cellular RNA polymerase II and transcription factors help the viral gene 
transcription.  Viral activators and repressors are also involved in transcriptional 
regulation of viral as well as host genes (4, 79).  MCMV gene regulation is not well-
studied compare to HCMV, so most of what is discussed here is about HCMV.  
 Many cellular factors have been shown to be involved in regulating a variety of CMV 
promoters.  Some of those factors activate and some repress the CMV promoters that are 
discussed here respectively.  When the virus enters into cells, it activates several cellular 
transcription factors such as myc, NF-kB and mitogen activated protein kinases ERK1, 
ERK2 and p38 (79).  In fibroblasts, extracellular-signal-regulated kinases (ERKs), 
members of the MAPK family are activated by the inhibition of an ERK-specific 
phosphatase upon HCMV infection (80).  Several cellular factors are regulated by the 
MAPK pathway, mainly factors that are involved in HCMV’s early gene regulation. 
Activated substrate of ERK kinase up regulates the activity of cAMP response-element-
binding protein (CREB) (81).  Previous studies on HCMV have shown in infected cells 
that ATF-CREB interacts with IE2 protein (the homologue of MCMV IE3) to trans 
activate the early UL112/UL113 promoter (82).  ATF/CREB proteins up regulate the 
transcription of number of promoters when bound to cAMP responsive elements (CRE) 
upon the phosphorylation of cAMP dependent PKA upon infection with MCMV (83).  
Interferon gamma inducible protein 16, a cellular protein interacts with tegument protein 
pp65 (UL83) and activates the major immediate early promoter MIEP (84).  Activator 
protein 1 (AP1) and necrotic factor kappa beta (NF-kβ) sites that are present in the major 
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immediate early enhancer were found to be important for the activation of MIEP in 
transfection assays (85).  Mutational analysis of the consensus sequence for PEA3 that is 
present in late gene UL75 showed that a PEA3 like element is involved in its activation 
(86).  According to previous studies, SP1 transcription factor contains a zinc finger 
protein motif, by which it binds directly to DNA and enhances gene transcription (87, 
88).  SP1 binds to GC-rich elements and is derived from a single gene product (89).  It is 
known to undergo heavy posttranslational modifications (90).  Several studies support 
that SP1 involves in the regulation of herpes virus gene expression and HCMV infection 
increases mRNA levels, proteins and SP1 binding activity (91-93).  It has been shown 
that attachment of glycoproteins from HCMV to the cell surface up regulates the SP1 
induction and IE2 of HCMV can physically interacts with SP1 to increase transactivation 
(91, 94).  IE2 protein may be increasing this SP1 DNA binding by releasing the inactive 
SP1. This SP1 binds to the SP1 sites in p65 and p105/p50 promoters and upregulates NF-
kB (93).  It has been well documented that SP1 interacts with general transcription 
factors for basal transcription activity (95).  
 Some cellular factors can also repress CMV promoters.  C/EBP interacts with NF-kB 
and represses NF-kB mediated activation of HCMV MIEP enhancer’s activity (96). 
Association with transcription activators and chromatin modifiers may lead to YY1 
mediated activation whereas association with other cellular repressors may lead to 
repression by YY1 (97).  It has been documented that YY1 is involved in the regulation 
of HCMV gene expression and it represses HCMV IE gene expression in non-permissive 
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T2 cells (98).  A study in MCMV shows that repressors bind to the viral promoters at the 
early stage of infection.  The number of repressors bound to these promoters is decreased 
once the RNA polymerase and acetylated histones bind to these promoters to activate 
their expression.  Viral repressor recruitment increased and occurs in a promoter specific 
manner during latency and YY1 and core binding factor 1 (CBF-1) act as repressors and 
play an important role during repression leading to latency in MCMV (99). 
 Viral proteins are involved in the regulation of viral promoters either directly or via 
cellular factors. Immediate early genes IE1 and IE2 (IE3 in MCMV) are spliced variants 
expressed from the MIEP.  IE1 and IE2 proteins can activate many viral and cellular 
promoters and regulate temporal expression of HCMV genes (100).  Work by Harel and 
Alwine (101), suggests that activated ERK play a role in regulating IE2 mediated 
transcription.  It has been shown that IE2 mediated transactivation occurs via synergy 
between SP1 and IE2.  This transactivation is evidently increased, when TBP is recruited 
by the promoters (102).  A study shows that IE1 and IE2 regulate MIEP by interacting 
with NF-kB.  Deletion of the MIEP enhancer or mutations in NF-kB sites in the MIEP 
abolished expression from the MIEP and viral replication (103).  IE1 and IE3 in MCMV 
are homologs of IE1 and IE2 in HCMV, which are regulated in a similar mechanism 
discussed above in HCMV.  
 Since virus attachment, and entry of the tegument proteins up regulate signal 
transduction pathways that can promote different viral promoter’s transcription (94, 104). 
Tegument proteins are known to regulate viral gene expression. Tegument protein pp71 
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accumulates at nuclear domains (ND10) upon HCMV infection.  This occurs via Daxx 
binding to SUMO-modified PML and transports pp71 to ND10.  All this happens before 
IE1 protein production.  Accumulated pp71and interaction with hDaxx is important for 
efficient infection and to enhance IE transcription at ND10 (105-108).  Attachment of 
HCMV (glycoproteins gB, gH) is sufficient to induce initial cellular signal transduction, 
which up regulates SP1 and NF-kB and help viral gene expression (94).  Tegument 
protein pp71 plays a crucial role in activating immediate early gene in the beginning of 
lytic infection  (109).  In HCMV, pp71 activates US11 gene via IE proteins and ATF-
CREB sites contribute to the activation of US11  (110) .  
 A wide variety of both viral and cellular factors can mediate viral promoter regulation. 
Very little is known about the promoter regulation of MCMV as compared to HCMV.  
The promoter studied in this project is for m143, which is essential for the virus.  This 
promoter requires viral infection to be upregulated and immediate early genes (IE1/IE3) 
can activate this promoter (68).  My studies on m143 have expanded the knowledge 
about gene regulation in MCMV and similarity to HCMV gene regulation. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Primer Design 
A series of 5’ end primers were designed using the m143 promoter region 
sequence. These primers were designed to make a series of promoter deletion mutants 
differing by approximately 100 bases.  A common 3’ reverse primer was used. The 
designed primers are shown in the Table 1. The constructs are shown in Figure 3. 
Primer 
Name 
Primer Sequence (5’-3’) Annealing Temperature 
(0C) 
AnnealingTemperature 
 used (0C) 
-787 
Forward 
TACTCGCGTCCGCCGTATCAC  58.26 53.3 
-728 
Forward 
GGCGGCATGAGACTACGGTG 57.93 55.4 
-620 
Forward CAACACCACGACCCGCTACC 57.93 59.3 
-511 
Forward 
TATCGCGACCGGGCTCGAAC 57.93 55.4 
-403 
Forward 
TCGTGGTCGGCAGCGTGTTG 57.93 55.4 
-315 
Forward 
GAAACGGCCGTCCTACCAGGTG 60.43 58.4 
-205 
Forward 
CGGCGTATGCCGTCACGATG 57.93 55.4 
Reverse  GGCAACCACCTCTCTGCTGTGG 60.43 - 
 
TABLE 1. Forward and reverse primer sequences designed to make deletion mutants 
from the full-length promoter sequence by deleting approximately 100 bases. These 
primers were used to amplify the deletion mutants.  
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FIG. 3. Full length (-787) promoter and designed sequential deletions.  
 
Polymerase Chain Reaction. PCR was done to amplify the deletion mutants 
using the primers shown in Table 1. DNA from infected cells was used as a template.  
DNA from uninfected cells was used as a negative control.  Total PCR reaction mixture 
was made up to 50 ul contained 25 ul of Amplitaq gold® 360 master mix (2X) (Applied 
Biosystems, Foster City, CA, USA), 2.0 ul of GC enhancer, 1.0 ul of forward primer (0.2 
uM), 1.0 ul of reverse primer (0.2 uM), template DNA (1 ug) and the rest is PCR grade 
water to make it up to 50 ul.  The Amplitaq gold system has an antibody that is blocking 
the active site of the polymerase, when heated at high temperatures this gets released and 
the DNA polymerase is active. This reaction was run with a hot start that was set as pre 
denaturation at 94 0C for 5 min. The program used was: denaturation at 94 0C for 1.0 min, 
annealing at primer specific temparature for 1.0 min, extension at 72 0C for 1.0 min, 
repeated for 34 cycles with a final extension at 72 0C for 5 min to improve complete 
double strand production.  PCR products were run on 1% agarose gels and the products 
were purified using the QIAquick Gel Extraction Kit (Qiagen Sciences, Maryland, USA) 
following the protocol from the kit.  
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TA cloning 
 TA cloning was done with purified PCR products of the expected size.  These 
were cloned into a PCR® 2.1-TOPO plasmid by topoisomerase following the company’s 
protocol (InvitrogenTM by Life Technologies, Carlsbad, CA, USA) and used for 
transformation. 
Bacterial transformation. Each TOPO TA cloning product was added to 
chemically competent E. coli (One shot TOP10 by Invitrogen), and heat shocked for 1.0 
min and incubated 1.0 hour for recovery following manufacturer’s protocol.  
Transformed E.coli was spread on LB Agar plates with kanamycin (Kan) antibiotic (50 
ug/ml) and X-gal at 40 ug/ml.  Kanamycin was used because the TOPO vector contains 
ampicillin and kanamycin antibiotic resistance, and kanamycin is less likely to have 
satellite colonies than ampicillin. X-gal was used for blue white colony selection.  The 
plates were incubated overnight at 37 0C.  White colonies and pale blue colonies were 
selected for further analysis. White colonies are the results of disruption of lac Z 
expression in the plasmid. Blue colonies result from lac Z expression from self-ligated 
plasmid.  Pale blue colonies were chosen because some of our small constructs might not 
disrupt lac Z expression. Bacteria from white or pale blue colonies were grown overnight 
at 37 0C in 3.0 ml of liquid LB media with kanamycin (50 ug/ml).  Plasmid DNA was 
isolated from the liquid cultures at around 16 hours using either the QAIGEN miniprep 
kit (QAIGEN, Sciences, Maryland, USA) following their protocol or using our lab made 
solutions.  Miniprep protocol from our lab as follows: 1.5 ml of overnight culture was 
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transferred into a 1.5 ml eppendorf tube and centrifuged at 6000 g for 10 min.  
Supernatant was removed and the bacterial pellet was air dried. This pellet was 
resuspended in 100 ul of ice-cold GTE solution I (25 mM Tris, pH8.0, 50 mM glucose, 
10 mM EDTA, 100 ug/ul RNAse A) by vortexing and pipetting up and down. This was 
incubated on ice for 5.0 min.  Next 200 ul of fresh solution II (10% SDS and 1M NaOH) 
was added and mixed by inversion.  This tube was incubated on ice for 3 min. then 150 ul 
of solution III (299.5 mM of KAcetate in 40 ml of water and adjusted pH with glacial 
acetic acid to 4.8, final volume was made up to 100 ml) was added, mixed by inversion 
and incubated on ice for 5.0 min.  The tubes were centrifuged at 6000 g for 4 min to 
pellet the debris.  Supernatant was transferred to a fresh 1.5 ml tube and 450 ul of 
phenol/chloroform was added in fume hood, mixed by vortexing and centrifuged at 6000 
g for 2.0 min.  The aqueous phase was transferred to a fresh tube, 900 ul of 100% ethanol 
was added, mixed and incubated for 2 min at room temperature.  This was centrifuged for 
4.0 min at 6000 g, to pellet the plasmid DNA, and supernatant was removed.  The 
plasmid DNA pellet was washed with 70 % ethanol and centrifuged for 1.0 min at 6000 g. 
Supernatant was removed and plasmid DNA was air-dried. The plasmid DNA was 
resuspended in 50 ul of sterile water.  
Restriction Digestion. For the confirmation and orientation of PCR products, the 
cloned deletion mutants were screened for insert using BamHI digestion.  This enzyme 
was used because all the PCR products have a BamHI restriction site close the 
transcription start site.  All the enzymes used in this project were purchased from New 
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England BioLabs (Ipswich, MA).  Restriction digestion mixture with BamHI (10 U), 1X 
NEB buffer 4, 3.0 ul of plasmid DNA and water was incubated over night at 37 0C. 
Negative control tubes contained everything in the mixture but no restriction enzyme, 
which shows the activity of enzyme.  This mixture was run on 1.2 % agarose gels to 
check the orientation.  
Sequencing 
After confirming the correct constructs, they were sequenced using M13 labeled 
primers on a LICOR 4300 sequencer to ensure that there are no mutations, mismatches or 
deletions.  We used the sequitherm EXCELTM II DNA sequencing kit for our sequencing. 
Sequencing reaction mixture was made with 2.25 ul of M13 800 IRDye labeled forward 
and M13 700 IRDye labeled reverse primers (1 pmol/µl) that have the complementary 
sequence in PCR2.1TOPO vector, 7.65 ul of template plasmid DNA (250 ng), 8.10 ul of 
3.5 X sequitherm excel buffer II, 1.12 ul of sequitherm excel II DNA polymerase (5 
U/ml). Four µl of this premix was added in each tube containing 2.0 µl of ddATP, 
ddTTTP, ddGTP, or ddCTP termination mix.  This mixture was run on a thermocycler 
with pre- denaturation (95 0C for 5 min), denaturation (95 0C for 30 sec), annealing (500C 
for 15 sec), elongation and (70 0C for 1.0 min and repeated for 29 cycles), extension (72 
0C for 5 min).  The sequencing products were stored at -20 0C.  Three µl of stop solution 
was added to all reaction products and the mixture was heated at 95 0C for 3 min before 
1.7 µl of sample was loaded in each well of the sequencing gel.  Sequencing gels were 
allowed to run for 8 hours to overnight depending on the product size.  The primers used 
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for sequencing are M13 forward primer (5’ G TAA AAC GAC GGC CAG 3’) and M13 
reverse primer (5’ CAG GAA ACA GCT ATG AC 3’).  The sequences obtained from 
sequencing were analyzed by BLAST from NCBI to check the sequences for similarity 
with the published MCMV sequences before sub cloning into a reporter plasmid. 
Sub-cloning 
In order to study the regulation of the m143 promoter we subcloned the constructs 
into a reporter plasmid.  The Clontech SEAP reporter plasmid (PT3057-1, Clontech, 
Moutain Veiw, CA, USA) which uses a secreted embryonic alkaline phosphatase (SEAP) 
as a reporter molecule to monitor the promoter activity was used.  The confirmed and 
sequenced constructs were digested using EcoRI restriction enzyme (10 U).  This enzyme 
was used because the insert in the multiple cloning site (MCS) of PCR 2.1 TOPO plasmid 
is flanked by EcoRI sites and there is an EcoRI site upstream of the SEAP gene in the 
MCS. The SEAP plasmid was digested with EcoRI (10 U) and treated with Antarctic 
phosphatase (5 U) with 1X phosphatase buffer for 1 hour at 37 0C to avoid self-ligation 
by removing the phosphates at the ends of the linearized plasmid.  Ligation of the gel 
purified insert and linearized reporter plasmid was set at a 3:1 molar ratio of insert to 
vector for 24 h at 4 0C using T4 ligase (5 U) with 1X ligase buffer.  As previously 
described, ligation mix was transformed into chemically competent E.coli, spread on an 
ampicillin (Amp) (50 ug/ml) plate, and incubated overnight at 37 0C. Ampicillin was 
used because the SEAP reporter plasmid has ampicillin resistance.  The colonies were 
analyzed for the orientation of insert in the vector using BamHI (10 U) digestion (Figure 
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4 A and B).  Large-scale plasmid preparations were made using the Fast Ion Plasmid 
Maxi Kit (MIDSCI, IA, USA) following manufacturer’s protocol.  We were not 
successful in subcloning the full-length promoter into the reporter plasmid directly so we 
chose to subclone in two steps. The full-length (-787) construct in PCR 2.1 TOPO was 
digested using KpnI and BglII and this fragment was put into the -315 construct that was 
digested with KpnI and BglII. Some of the PCRs were not successful, so an alternate 
method was used, using restriction enzymes in the constructs that had been successfully 
sub cloned (Figure 4 C).  The -511 construct was made with Acc65 I and NruI from the 
full-length construct. First the full-length construct was digested with Acc65 I, then the 
cohesive ends were filled with DNA Polymerase I, Large (Klenow) Fragment (1 U/ug 
was used) to make it blunt ended and gel purified. When this fragment was religated, it 
created a new restriction site for SnaBI. We used Acc65I because it is an isoschizomer of 
KpnI and produces a 4-base 5´ extension whereas KpnI produces a 4-base 3´extension. 
This allowed us to fill in the 5’ overhangs to form blunt ends and avoid Klenow’s 
possible 3'→5' exonuclease activity.  This plasmid was then digested with SnaBI and 
NruI enzymes (5 U each), NruI is a blunt end cutter and cuts twice in the insert and 
SnaBI, also a blunt end cutter, cuts once at the newly generated site.  After removing the 
SnaBI-NruI fragments, the plasmid was religated. The +4 construct was made by 
religating the BglII (5 U) digested plasmid from the -205 construct. To make the -124 
construct, BglII digested +4 and a BamHI-BglII fragment (-124 to +4) was purified from 
the full-length  construct (-787)  and inserted into the BglII  site of +4 construct.  
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Cell cultures 
Murine NIH3T3 fibroblasts cells (America Type Culture Collection (ATCC) CRL 
1658, Rockville, MD) that are permissive for MCMV were grown in Dulbecco's 
modified Eagle's medium (DMEM) (GIBCO® by Life Technologies, Carlsbad, CA, USA) 
that was supplemented with 10% bovine calf serum (BCS) (GIBCO® by Life 
FIG. 4. Analysis of insert orientation and restriction enzymes used: A. correct 
orientation of the insert in pSEAP plasmid after subcloning the digested insert into 
pSEAP multiple cloning site. B. Incorrect orientation of the insert into pSEAP. C. 
Full-length construct with the enzymes used in making various constructs in SEAP 
reporter plasmid as described. Black lines indicate the MCS in the SEAP reporter 
plasmid. F: Forward primer, R: Reverse primer from PCR.  
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Technologies, Carlsbad, CA, USA).  This is referred as DMEM complete media in later 
sections.  These cells were grown in a CO2 water-jacketed incubator (NUAIRE) at 37 0C 
with 5% CO2. The cells were maintained on a strict 3T3 regimen, which means they were 
split every 3 days and seeded at 3 x105 cells in a 75 cm2 growth surface area flask 
(MIDSCI, Valley Park, MO, USA).  For splitting, cells were washed with PBS-EDTA 
(136.89 mM Nacl, 2.68 mM Kcl, 10.14 mM NA2HPO4, 1.76 mM KH2PO4, pH-7.4, 11.1 
mM dextrose, 1.36 mM EDTA, 0.2 u filter sterilized) after removing the media. Then the 
cells were trypsinized using 1.0 ml of 0.5% trypsin in PBS-EDTA for 30-60 sec.  
Trypsinized cells were re-suspended in DMEM complete media to inactivate the trypsin.  
The cells were diluted 1:10 using 0.1% trypan blue dye to count the number of viable 
cells before seeding.  
Virus Stocks 
We used MCMV [Smith strain (ATCC VR 194)] for infections.  NIH 3T3 
fibroblast cells were seeded at 1x106 into a 150 cm2 flask (MIDSCI, Valley Park, MO, 
USA).  Twenty-four hours later these cells were infected at a multiplication of infection 
(MOI) of 0.001. Virus stock was harvested when there was 100% cytopathic effect (CPE) 
in the flask (around 5 days).  To harvest the virus, the cells were frozen at -80 0C for 10 
min and thawed.  This will break open the cells and release the virus from inside the cells. 
These cells with media were collected into a tube and centrifuged at 425 g for 10 min to 
get rid of cell debris.  The supernatant was collected into fresh tubes, aliquoted into 
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polypropylene cryogenic vials and stored at -80 0C.  All virus stocks were then quantified 
by standard plaque assay. 
UV Inactivated virus stock. After harvesting, the virus stock was divided in half 
into two sterile tubes, one half was poured into a sterile 60 mm petri dish and treated with 
UV radiation for 2 min in UV cross linker (FB-UVXL-1000, Fisher Biotech®), rocked to 
mix and irradiated for 2 more minutes.  The other half was left untreated. Then these 
stocks were aliquoted and quantitated using standard plaque assay to confirm virus 
inactivation. In experiments using UV inactivated virus the parental stock was used for 
control infections. 
Plaque Assay. NIH3T3 cells were seeded into 12 well plates (MIDSCI, Valley 
Park, MO, USA) at 1x 105 cells per well. Cells were infected 24 hours later.  Tenfold 
serial dilutions of the virus stock were made in sterile tubes.  One hundred ul of the virus 
inoculum was used in duplicate wells with each dilution.  Cells were infected for 1 hour 
by rocking every 15 min.  After removing the inoculum the cells were overlaid with 1X 
DMEM complete media with 0.5 % agar.  Then the plates were incubated for 5 days. At 
day 5 cells were fixed using 10 % buffered formalin.  Twenty-four hours later overlay 
and formalin were removed and plates were dried.  Then the cells were stained with 1% 
crystal violet to facilitate counting of plaques.  The average of 4 wells (2 dilutions) was 
used to get the virus titer of the stock. 
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Transfections 
NIH3T3 cells were seeded at 6x105 in a 25 cm2 flask.  Twenty-four hours later 
they were transfected with 9.0 ug of reporter plasmid using 18.0 ul of TransfectinTM lipid 
reagent (BIO-RAD, Hercules, CA, USA) at a 2:1 ratio of Transfectin to plasmid. Twenty-
four hours post transfection the cells were counted and split into triplicate wells of a 12 
well plate at equal cell densities. After an additional 24 hours, transfected cells were 
infected as described for the plaque assay at an MOI of 2 which would be sufficient to 
infect almost every cell, mock infected (media without virus) or treated with UV 
inactivated virus at a dilution comparable to the parental virus.  Twenty fours post 
infection the cells were examined for CPE to confirm infection.  Supernatants were 
collected to perform the SEAP assay and cells were harvested for DNA for normalization 
of transfection efficiencies.  
Co-Transfections. NIH 3T3 fibroblast cells were transfected with 6.0 ug of 
reporter plasmid along with 6.0 ug of a plasmid that expresses both IE1 and IE3, or IE1 
alone or IE3 alone using the same 2:1 ratio of Transfectin to plasmid and the cells were 
handled as for mock infection to avoid inconsistences of SEAP levels with other 
transfections.  In some co-transfections the cells were treated with UV inactivated virus 
instead of media.  Plasmids encoding MCMV immediate-early genes (IE3 and IE1/IE3) 
were kindly provided by Dr. Martin Messerle (University of Halle, Halle, Germany).  
The IE1-GFP tagged plasmid was generously provided by Dr. Qiyi Tang (Ponce School 
of Medicine, Ponce, Puerto Rico). 
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PFA treatments. Phosphonoformic acid (PFA, Foscarnet) is a drug that inhibits 
viral DNA replication as described in the antiviral therapy section.  PFA treatment was 
done to inhibit late gene expression.  After infecting the cells, DMEM complete media 
mixed with 50 ug/ul of PFA (Sigma-Aldrich, St Louise, MO, USA) was added for 24 
hours.  As mentioned above replicate wells received either normal media or media with 
PFA.  
Normalization. DNA was isolated from cells using the MasterPureTM DNA 
purification kit (Epicentre® Biotechnologies, Madison, WI, USA) following the 
company’s protocol.  This DNA was used for quantitative PCR for the normalization of 
transfection efficiencies.  Cellular gene primers for poly A binding protein (PABP) were 
used as a loading control to normalize equal amounts of cellular DNA (Table 2).  
Ampicillin primers (Amp) were used for the plasmid DNA (Table 2).  Ampicillin primers 
could not be used to look for transfection efficiencies in co-transfected DNA samples 
because the IE1/IE3 plasmids also had Amp resistance.  Hence we used primers for SEAP 
to see relative copies of reporter plasmid DNA present in co-transfected samples (Table 
2).  The qPCR reaction mixture contained: 12.5 ul of 2X  iQTM SYBER® green super mix 
(BIORAD, CA, USA), 1 µl of each forward and reverse primers (10 mM), 10.0 ng 
template DNA, and double distilled water.  All the reactions were run in duplicate.  PCR 
was done using the program conditions; 1 cycle of 3 min at 95 0C, followed by 35 cycles 
of 30 sec at 95 0C, 30 sec at 60 0C, and 30 sec at 72 0C which had previously been 
determined to work well with all the primers.  Fluorescence was read after each cycle.  
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After 35 cycles, final incubation was carried out for 5 sec at 72 0C.  Melting curves were 
done at starting temperature 65 0C, ending temperature 90 0C, with increments of 0.1 0C, 
and hold for 1sec.  After completion of melting curves, there was a final extention at 72 
0C for 1 min followed by holding at 10 0C.  Quantitative PCR products were run on 1 % 
agarose gels to check for a single product of the correct size. For normalization, first the 
loading control was analyzed to ensure this was comparable between samples.  Any 
differences in the loading control were used to correct for the plasmid of interest.  Then 
we checked to see if there is any difference in the amount of plasmid of interest.  If they 
were not the same then the fold difference was used to correct the SEAP levels.  Cycle 
number varying in the loading control (PABP) means the DNA quantification is wrong.  
Cycle number varying in the plasmid of interest (AMP/SEAP) but not varied in the 
loading control means transfection efficiencies are different.  This allowed us to identify 
whether any difference in SEAP levels is coming from different transfection efficiencies 
or the difference between the reporter constructs. The primers used in qPCR are shown in 
Table 2. 
 
Primer Name Forward primer (5’-3’) Reverse primer (5’-3’) 
PABP GCAATGCTGGCCCAGTGATCATG AAGGCCAGGGACGTCCTCACTGA
C 
Ampicillin ATCGTTGTCAGAAGTAAGTTGG GCCGCATATCACTATTCTCAG 
SEAP AGACCTTCATAGCGCACGTC CATGTCTGCTCGAAGCGGC 
 
 
TABLE 2. qPCR primers used in the normalization of transfection efficiencies 
  
32  
SEAP Assay 
Culture supernatants were collected and centrifuged at 10,621 g for 4 min to get 
rid of any cells and supernatant was transferred to fresh tubes.  These samples were 
frozen at -20 0C until ready to do the assay.  Initial studies indicated that freezing and 
thawing of the samples did not significantly affect SEAP activity.  The assay was 
performed in triplicates.  Samples were assayed using the Great EscAPeTM Fluorescent 
SEAP assay (Clontech).  In this assay 75.0 µl of 1X dilution buffer was added to 75.0 µl 
of supernatant in 0.5 ml PCR tubes (BIORAD, Hercules, CA, USA) and heated at 65 0C 
for 30 min in a PTC-200 Peltier thermal cycler (MJ Research) to inactivate cellular 
phosphatases.  The samples were kept on ice for 2 min and cooled to room temperature, 
and transferred into triplicate wells of a micro plate-96 well plate with clear bottoms and 
black sides (MID-SCI, St Louise, MO, USA).  Seventy five µl of assay buffer was mixed 
with 3.0 µl of substrate, [1 mM 4-methylumbelliferyl phosphate (MUP)], which was 
diluted in 1X dilution buffer and added to each sample well that had sample.  The plates 
were incubated for 60 min in the dark at room temperature on a shaker.  Fluorescence 
was detected using the Synergy HTS fluorometer at 360 nm transmittance, 340 nm 
absorbance and at sensitivity 60.  SEAP activity in the reporter constructs was compared 
to pSEAP2-Basic (no promoter).  We used a positive control plasmid under the control of 
SV40 promoter in our initial studies to check if the assay is working. 
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Statistical analysis 
One-way ANOVA was used to determine statistical significance between 
treatments and student t-test was used to compare the individual constructs.  P values of 
≤0.05 were considered significant. 
Site directed mutagenesis 
  Based on the results from the SEAP assay, we performed site directed 
mutagenesis of identified important DNA sequence regions. 
 Primer Designing. The most critical part in primer design is introducing a 
restriction site to destroy the consensus site and to simplify screening.  The primers were 
designed that are complementary to each other so that they could anneal to the same 
sequence on the opposite strands of the plasmid.  These primers were used in sequential 
PCR reactions. For the 1st round, one reaction was performed with the forward primer 
used to generate the -205 or the -315 construct and the reverse mutated TATA primer.  A 
second reaction was done with forward mutated TATA primer and the common 3’ 
reverse primer (Table 1). In the 2nd round PCR, the PCR products from the 1st round were 
used as template with -205 or -315 construct forward and common 3’ reverse primer.  
The PCR was performed as described in the PCR section with an annealing temperature 
of 59.4 0C.  The final PCR product of the expected size was gel purified, TA cloned and 
screened for the designed mutation via restriction digestion.  The designed mutated bases 
are underlined, which makes a restriction site for BsrGI. 
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Original sequence: GATGGTGTAAAAGAGGGCCG 
Mutated Forward primer:  5’ GATGGTGTACACGAGGGCCG 3’ 
Mutated Reverse primer:  5’CGGCCCTCGTGTACACCATC 3’ 
Electrophoretic Mobility Shift Assay (EMSA) 
 The principle behind this assay is DNA runs slower when it is bound to a 
protein than DNA alone on acrylamide gels.  In this study we used oligonucleotides 
designed based on the deletion analysis. These oligonucleotides were end labeled with 
LICOR 700 IRDye to allow detection in the gel.  Nuclear extracts were prepared from 
mock infected or infected NIH3T3 cells as described in nuclear extraction preparation. 
The designed oligonucleotides are shown in the Table 3. 
 
Site Name Forward primer (5’-3’) Reverse primer (5’-3’) 
TATA box GATGGTGTAAAAGAGGGCCG CTACCACATTTTCTCCCGGC 
Core binding 
factor 
TCTGTCTGGGTGTGGTCACCCGGA AGACAGACCCACACCAGTGGGCC
T 
SP1 GCCGTCACGATGTCCGCCCGCGAG
TTGTCG 
CGGCAGTGCTACAGGCGGGCGCT
CAACAGC 
 
 Nuclear Extraction preparation.  Cells were seeded into 60 mm cell culture 
dishes at a density of 2 x 105 and 24 hours later infected with MCMV at an MOI of 2 or 
mock infected.  Twenty-four hours post infection the cells were washed with PBS-EDTA, 
scraped from the surface of the dish in 1 ml of PBS-EDTA, transferred into a 1.5 ml 
eppendorf tube, and pelleted at 106 g for 10 min. The pellet was resuspended in 100 ul of 
TABLE 3. Designed oligonucleotides for EMSA, consensus-binding sites are underlined.  
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cytoplasmic extract (CE) buffer with detergent NP-40 (10 mM HEPES, 60 mM KCl, 1 
mM EDTA, 0.075% (v/v) NP40, 1mM DTT and 1:1000 diluted protease inhibitor 
[Protease inhibitor cocktail set III, CALBIOCHEM, La Jolla, CA] adjusted to pH 7.6).  
The samples were incubated on ice for 3 min and centrifuged at 239 g for 4 min. The 
cytoplasmic extract (supernatant) was collected into a new tube, glycerol was added to a 
final concentration of 20 % and stored at -80 0C.  The nuclei were gently washed with 
100 ul of CE buffer without NP-40 and centrifuged at 239 g for 4 min.  Supernatant was 
removed and 50 ul of nuclear extract (NE) buffer (20 mM Tris Cl, 420 mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, protease inhibitor cocktail set III and 25 % (v/v) glycerol, 
adjusted to pH 8.0) was added to the nuclear pellet. After resuspending by vortexing, salt 
concentration was adjusted to 400 mM by adding an additional volume of 5.0 M NaCl.  
This extract was incubated on ice for 10 min with periodic vortexing.  This extract was 
centrifuged at 10,621 g for 10 min to pellet any remaining nuclei. Supernatants were 
collected and stored at -80 0C. 
Western blotting. In order to check for cytoplasmic protein contamination of 
nuclear extracts we performed western blot analysis.  We used Bio-Rad’s western mini 
PROTEAN 3 apparatus for running the gel. Approximately 40 ug of nuclear extracts 
were separated by SDS-PAGE on 10 % gels and transferred to nitrocellulose at 4 0C 
overnight.  The mini wet trans blot system from Bio-Rad was used for transferring.  The 
membranes were then incubated in blocking buffer [5 % milk in TBS (150 mM NaCl, 10 
mM Tris pH 7.5)] for 1 hour, before primary antibodies were added at a dilution of 1:200 
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in blocking buffer.  Primary antibodies used were mouse anti- α tubulin for cytoplasmic 
protein and rabbit anti-e1 to confirm viral infection.  Then the membranes were washed 3 
times in TBS 0.1% Tween 20 with 5 min incubation to get rid of primary antibody.  
Secondary antibodies were added at 1:15000 in blocking buffer. The secondary 
antibodies used were fluorescently labeled goat-anti rabbit and goat-anti mouse.  The 
membranes were then washed again 3 times with TBS 0.1 % Tween 20.  The membranes 
were detected on the Odyssey CLx infrared imaging system (LI-COR Biotechnology, 
Lincoln, NE). 
 (i) Antibodies. Mouse anti-α-tubulin (clone B-5-1-2) was purchased from Sigma 
(Sigma-Aldrich, St. Louis, MO).  The generation and characterization of rabbit anti-e1 
antibody were previously described. Secondary antibodies used goat-anti rabbit IRDye 
800 CW and goat-anti mouse IRDye 680 RD from LICOR. 
 Protein Concentration Determination. We used the Bio-Rad DC TM protein assay 
kit. We followed the Bio-Rad’s microtitre plate protein assay protocol for determination 
of the concentration of protein in the extracts, using bovine serum albumin (BSA) as a 
standard. All BSA standard samples were performed in duplicates.  
 Oligo Preparation. Oligos were resuspended in 1X TE buffer (pH 7.5) to a final 
concentration of 20 pmol/μl. Five μl of forward IRDye 700 oligo and 5 μl of reverse 
IRDye 700 oligo were added into a new tube.  These oligos were annealed by placing the 
oligo set in a 100 0C heat block for 5 min. then slowly cooled to room temperature. The 
annealed oligos were diluted 1: 200 with di H2O and stored at 20 0C.  This stock was used 
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as a working oligo stock.  
 Gel Preparation and Binding Reaction. Denatured polyacrylamide of gels 4% or 
6% were prepared. The percent used depended on the oligo size.  The binding reaction 
was set up which included, 100 mM Tris, 500 mM KCl, 10 mM DTT; pH 7.5, 25 mM 
DTT/2.5%Tween® 20, NIH3T3 nuclear extract (5.0 μg) and 20 fmoles of annealed 
IRDye 700 primers.  We used mock and infected nuclear extracts in binding reactions.  
There were three control samples in which one tube contained just the labeled probe, a 
second tube contained labeled probe, and nuclear extract (Mock or infected) and the third 
tube contained labeled probe, nuclear extract (Mock or infected), and non-specific 
unlabeled DNA [non-specific competitor (Mutated TATA primers) 1 μg/ul,].  If the non-
specific unlabeled DNA cannot compete for binding that helps confirms specificity of the 
binding. Reaction mixtures were incubated for 30 min and 2.0 ul of 10X orange loading 
dye (LI-COR®) was added.  Mixtures were loaded on the polyacrylamide gel and run 
using Tris borate EDTA buffer (TBE) at half the concentration used for DNA agarose 
gels until the dye front was 2 inches from the bottom of the gel.  All of this was done in 
the dark at 4 0C because of the light sensitivity of the probe. Then the gel was detected on 
the Odyssey CLx infrared imaging system. 
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CHAPTER III 
 
RESULTS 
 
Identification of DNA sequences important for the m143 promoter. In order 
to identify what sequences are involved in the promoter regulation of m143, a series of 
nested deletion mutants of the m143 promoter were generated and tested for the ability to 
mediate expression of a secreted alkaline phosphatase in the pSEAP2-Basic plasmid. The 
presence of consensus transcription factor binding sites for factors previously found to be 
important for other herpesviruses promoters was noted. The regions were identified using 
transcription element search system (TESS) from the computational biology and 
informatics lab at University of Pennsylvania. These sites and the deletion mutants are 
shown in Figure 5 A and B respectively.  The numbers indicate location relative to the 
transcriptional start site (+1). 
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-787     AP4     SP1 
TACTCGCGTCCGCCGTATCACCACAGCTGGAAGTCGAGAGACGGTCCTCGG   
                      Gamma IRE_CS      -700      SP1                             
GTCGCGAGGGCGGCATGAGACTACGGTGTTTCGCTAGGGACTACTATCCCG 
           C/EBP                                SP1 
CCGATTTAGAGATTCGGTGGTGGAAAGATGATGGCGGTGGTGGTGCGCTG 
    ATF/CREB                                  SP1                     -600 
CCTCAAACGTCAAAACAACACCACGACCCGCTACCGTCCGGTAACGGGCT 
                                 SP1 
CTACCAAAAACATATCGACGTCTATGTGGACGGAGGCTTGGAGCACGTGTA 
      -500 
CTCGTGTCGAGTCAAGGGTATCGCGACCGGGCTCGAACTGCAGATCGTGAGG 
     AP-2 
TGGAAGGGCTACGCGAGAGGCGCGGGGAACTCGGTCGTCCTGTTGGCCCTG 
     YY1                 -400 
TTCATACCCGCGAGCGTCATGGCGGCGGTCGTGGTCGGCAGCGTGTTGATAC 
                                                          PEA3                                                     
GAAAGAAGAGCAAGGAACAGAGGAAGACGCGTAGGAGGTTCGGACGGCGC 
              -300          HSVIEREPEAT 
TCGGGACACGAGCCGAAACGGCCGTCCTACCAGGTGAAGAGACGCGCGGAA 
         YY1                     
CCGCCATGCGACCTACCGATGACCATCTGGTTCCGCGGCGACAACGTGATGA 
             -200    ATF/CREB                 SP1 
GCACTCAGGTCGAGGCCTGTCCGGCGTATGCCGTCACGATGTCCGCCCGCG 
      SP1                    ATF/CREB 
AGTTGTCGGACGCCTGGTCGAACGGGGACGGTCCGATCGTCACGGTCCCGG 
                            -100                      CORE BINDING FACTOR 
ATCCCAGCATTTGAGCGCGCCTCTGATCTGTCTGGGTGTGGTCACCCGGAT 
     TATA                                                                              +1                             TATA 
GTGTAAAAGAGGGCCGCGTAACTCCAGAAACGGTATACAGATCTCTGTTTCC 
 
ACAGCAGAGAGGTGGTTGCC 
A 
B 
 FIG. 5. M143 promoter region and deletion mutants: A. m143 promoter sequence 
used in this study. +1 indicates the transcriptional start site. The locations of consensus 
transcription factor binding sites are indicated. B. Map of deletion mutants used to 
analyze the functional binding sites involved in transcriptional regulation.   
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SEAP activity was assessed for mock and infected cells with each promoter 
reporter construct. In all cases, the phosphatase activity is expressed as fold increase over 
background.  The background activity from cells transfected with the pSEAP2-Basic 
plasmid, which contains no promoter, was set at 1 in every experiment.  Mock-infected 
SEAP levels for all the constructs were not significantly different than no promoter, 
indicating that cellular factors are not sufficient for detectable activity of the m143 
promoter (Figure 6).  SEAP levels from infected cells were significantly higher than 
uninfected indicating that viral factors are required for the activation from the m143 
promoter.  SEAP levels with the full-length promoter were 4 fold higher than -511, which 
means that there is at least one activator-binding domain within the deleted region.  This 
sequence contains several potential important binding sites including one of each AP4, 
Gamma interferon response element, C/EBP, ATF/CREB and 5 SP1 sites. Deletion of the 
next 196 bases led to 3.5 fold increased SEAP levels, which indicates the removal of a 
repressor-binding site. This region contains one each of AP2, YY1 and PEA3 sites.  
SEAP levels between the -315 construct and the -205 construct were not significantly 
different from each other. The sites present in this region, HSV IE repeat and YY1 are 
unlikely to be important for regulation of the m143 promoter.  Deletion of the region 
between -205 and -124 resulted in loss of all activity, which indicates that an activator-
binding site or sites were removed.  This region contains 2 ATF-CREB and 2 SP1 sites. 
SEAP levels of the +4 construct were the same as the background.  
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Newly synthesized proteins are required. It has been shown that the attachment 
of virus to the cell surface activates some cell signaling pathways (79).  Using UV 
inactivated virus allowed us to address the importance of these changes in activation of 
the m143 promoter.  Treatment with UV inactivated virus didn’t show any significant 
difference from mock infection (Figure 6), which indicates that tegument proteins from 
the virus entry and attachment of virus to the cell surface are not sufficient to activate this 
promoter.  
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FIG. 6. Viral infection is required for detectable activation from the m143 
promoter: NIH3T3 cells were transfected with the indicated promoter reporter 
constructs and were mock infected, infected at an MOI of 2 or treated with UV 
inactivated MCMV at the same dilution as the virus 48 hours post transfections. 
Supernatants were collected for SEAP assay 24 hours post infections. The level of 
activity is expressed relative to no promoter set at 1. n=3, error bars are std. error of 
means. Closed stars represent statistical significance between mock and infected. Open 
stars represent significant difference from the previous construct.  
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Immediate Early proteins (IE1/IE3) are sufficient for activation. Two 
important viral transcriptional regulators that are expressed rapidly after infection are 
splice variants (IE1and IE3) (54, 111).  To investigate the importance of IE1and IE3 for 
activation of the m143 promoter, the reporter plasmids were co-transfected with a 
plasmid expressing both IE1 and IE3.  The SEAP activity from co-transfections was 
significantly higher than background (no promoter) in all cases except the +4 construct as 
shown in Figure 7, SEAP activity in the full-length construct was 4 fold higher than the 
rest of the constructs, indicating that either IE1or IE3 are activating between -787 and  
-511 or other cellular factors may be enhancing the activation via this region.  There was 
no significant difference in SEAP activity levels from the -511 to -124 constructs. There 
was a significant decrease in the +4 construct from the -124 construct, indicating either 
IE1, IE3 or both activate via this region. Unlike infection (Figure 6), repression between  
-511 and -315 was not seen in co transfections, indicating that other viral proteins likely 
mediate the repression of the m143 promoter via this region.  The SEAP activity levels of 
the -124 construct in the presence of IE1/IE3 are double the SEAP activity levels from 
infections (Figure 6), indicating there may be other viral proteins repressing in this region 
as well.  There are two putative TATA boxes present one at -33 and another at +11. The 
+11 one was removed in the +4 deletion mutant.  Decrease in the SEAP levels between 
the -124 construct and the +4 construct support that TATA sequence present at -33 is 
more likely to be functional. 
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IE1 alone can activate m143 promoter. Since cytomegalovirus promoters may 
vary in the importance of IE1 and IE3 for regulation we next examined the ability of IE1 
alone to activate the m143 promoter (Figure 8).  Cells were co transfected with a plasmid 
that expressed IE1 alone along with the m143 promoter constructs. SEAP levels of all the 
constructs with IE1 co-transfection were above background except the +4 construct, 
indicating that the region required for activation by IE1 is in this minimal promoter. 
SEAP levels of IE1 co-transfections were much lower than the SEAP levels of IE1/IE3 
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FIG. 7. Immediate early proteins IE1/IE3 are sufficient to activate the promoter: 
NIH3T3 cells were co-transfected with a plasmid that expresses both IE1 and IE3, 
and treated as mock infection. Supernatants were collected for SEAP assay 48 hours 
post transfections. The level of activity is expressed relative to no promoter set at 1. 
n=3, Error bars are std. error of means. Closed stars represent statistical significant 
difference from no promoter. Open stars represent significant difference from the 
previous construct. 
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co-transfections (Figure 7) in all the constructs, indicating that IE1 alone only weakly 
activates the m143 promoter. IE1 likely cooperate with IE3 to activate this promoter. 
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Deletion Mutants 
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IE1
FIG. 8. IE1 alone can activate the m143 promoter: NIH3T3 cells were co-transfected 
with a plasmid that expresses IE1. Supernatants were collected for SEAP assay 48 hours 
post transfections. The level of activity is expressed relative to no promoter set at 1. 
n=3, Error bars are std. error of means. Closed stars represent statistical significance 
between treatments. Open stars represent significant difference from previous construct. 
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IE3 alone can activate the m143 promoter. SEAP levels of all the constructs 
with IE3 co-transfection were not significantly different from the background SEAP 
levels except full-length promoter (Figure 9), indicating that IE3 alone can activate the 
m143 promoter weakly.  Although IE1 and IE3 alone can activate weakly, IE1 and IE3 
appear to work synergistically to activate the m143 promoter.  
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Deletion Mutants 
IE3 co-Transfections 
CONSTRUCT ALONE
IE3
FIG. 9. IE3 alone can activate the m143 promoter: NIH3T3 cells were co-
transfected with IE3 plasmid. Supernatants were collected for SEAP assay 48 hr post 
transfections. The level of activity is expressed relative to no promoter set at 1. n=3, 
Error bars are std. error of means.  
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Late proteins are not involved in the regulation. Since the data indicates that 
other viral proteins are also involved in regulation of the m143 promoter, we did 
treatment with phosphonoformic acid (PFA, foscarnet) to determine whether late proteins 
were involved (Figure 10).  PFA is a drug that inhibits viral DNA replication thus 
preventing late gene expression.  SEAP levels in the presence of the inhibitor were not 
significantly different from infected without drug in all cases, indicating that late viral 
proteins are not involved in the regulation of m143 promoter. Thus the viral regulators 
are likely to be early proteins. 
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FIG. 10. Late viral proteins are not involved in regulation of the m143 promoter: 
NIH3T3 cells were transfected and treated as in Figure 6 except 6 ul/ml of PFA was 
present throughout the infection in the indicated samples. Supernatants were collected 
for SEAP assay 24 hours post infections. The data shown above are the mean and the 
standard error of the mean of three individual experiments.  
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Viral factors are involved in m143 promoter regulation. In order to see if 
tegument or capsid proteins are involved in the repression of m143, we did co-
transfections with IE1/IE3 and treated with UV inactivated virus (Figure 11). There was 
no significant difference in all the constructs between IE1/IE3 co-transfections without 
UV inactivated MCMV and with UV inactivated MCMV, indicating that tegument 
proteins and capsid proteins together are not involved in the repression of the m143 
promoter. 
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FIG. 11. Viral proteins enhance/repress m143 promoter activation: NIH3T3 cells 
were co-transfected as in Figure 7, except that replicate wells were treated with UV 
inactivated virus as in Figure 6. Supernatants were collected for SEAP assay 48 hours 
post transfections. The data shown above are the mean and the standard error of the 
mean of three individual experiments. Open stars represent significant difference from 
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Mutational analysis of the putative TATA box 
To determine if the putative TATA box in the -124 construct is important, Several 
PCR attempts were done using the mutated primers of TATA box and the primers for the 
-315 or the -205 construct as described in the methods section. Plasmid DNA of the -315 
or the -205 construct was used as template.  After TA cloning of the gel purified PCR 
product into PCR2.1 TOPO, clones were screened for the mutated insert using BsrGI. We 
didn’t get the mutated TATA insert.  So the template was changed to DNA from infected 
cells, because we used the same template in our initial PCR while making deletion 
mutants. This time the PCR product was TA cloned into pGEM-T easy vector system I 
(Promega, Madison, WI).  The clones were again screened for the introduced BsrGI 
restriction enzyme site.  But we were not successful in getting the mutated plasmid. It 
may be because one of the mutated fragments from the mutation to the common 3’ 
reverse primer is only 70 bases long and might have been confused with primer dimers. 
Probably conditions need to be worked out more or a different method may need to be 
used.  
Identification of transcription binding factors that are involved in the regulation of 
the m143 promoter 
Electrophoretic mobility shift assay was performed to identify if any proteins are 
binding to specific SP1 and TATA binding sites in the m143 promoter.  A SP1 site was 
chosen because of activation from m143 promoter wherever this site is present in the 
sequence. Nuclear extracts from mock infected and infected cells were prepared as 
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described in the methods section.  These extracts were tested for cytoplasmic 
contamination by western blotting (Figure 12).  With anti tubulin, there was only a slight 
contamination with cytoplasmic proteins in the nuclear extracts. After quantifying the 
nuclear extracts they were used for EMSA as described. 
 
 
 
 
FIG. 12. Western blot: western blots for cytoplasmic protein contamination check in 
infected and mock nuclear extracts (NE). CE: cytoplasmic extracts. The red indicates 
tubulin and green indicates viral nuclear protein e1. 
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To examine the reproducibility of binding patterns, we used three different 
nuclear extracts.  The patterns were similar for all three extracts, which indicates that the 
binding is reproducible.  The labeled SP1 probe alone seen in the first well is a control for 
migration and so the shift of the probe with bound protein can be differentiated on the gel 
(Figure 13).   To see if the binding is specific, we used a non-specific unlabeled DNA 
competitor both with mock and infected nuclear extracts. Addition of nonspecific 
competitor helps to reduce the concentration of nonspecific proteins and can indirectly 
enhance the binding of specific proteins to the labeled probe as seen for the band 
indicated by the arrow.  Mock nuclear extracts were used to see if the proteins or 
complexes that bind to the probe are cellular or viral proteins addressed in more detail in 
the discussion.  Additional bands on the gel show nonspecific binding because binding is 
reduced by the non-specific competitor. 
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   We wanted to see if anything binds to the putative TATA sequence of the m143 
promoter.  TATA labeled oligo was used to see if any proteins from nuclear extracts are 
binding to this sequence.  Figure 14 shows the binding of multiple complexes to the 
labeled oligo in mock and infected nuclear extracts.  Since the results with the competitor 
FIG. 13. EMSA for SP1 binding: EMSA was done for the SP1 binding site present at 
-187 to -178 with three different nuclear extracts (NE). Conditions used are described 
in materials and methods. The band indicated with an arrow is likely a specific 
interaction.  
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used were inconsistent, the specificity is unclear.  The conditions may need to be worked 
out further. 
 
 
 
 
 
 
FIG. 14. EMSA for TATA binding: EMSA was done for TATA binding site with 
two different nuclear extracts (NE). Conditions used are described in materials and 
methods. 
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CHAPTER IV 
 
DISCUSSION 
 
Identification of DNA sequences important for the m143 promoter 
 
 
 
M143 is an essential gene of MCMV and is required for inhibition of the PKR 
mediated antiviral pathway (70, 71).  Because it is essential for the virus, understanding 
m143 gene regulation, especially by viral factors, could help in developing new antiviral 
therapeutics.  Previously it has been shown that expression from the m143 promoter is up 
regulated upon viral infection by Hanson et al (68).  In their work they used luciferase as 
a reporter, which is more sensitive than the SEAP reporter system and saw detectable 
activation in mock infections. Despite this difference, our system is very useful since the 
normal environment would be infected cells.  This is a continuation of the same work to 
identify the regulatory elements of the m143 promoter.  Deletion analysis of a promoter 
SP1
- 787         -511                        - 315   -205                  -124       +1       +38   
TATA
ATF/CREBSP1
ATF/CREB
YY1
SP1PEA3AP2SP1
SP1
ATF/CREB
GammaIRE
AP4
C/EBP
Core Binding Factor
BamHI
FIG. 15. Consensus transcription binding sites: The locations of consensus 
transcription factor binding sites on the m143 promoter. Green color font sites indicate 
cellular activator sites and red color indicates repressor sites. 
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is one of the common methods used for identification of important regulatory regions of 
that promoter.  All of the regions identified as important for activation contain consensus 
binding sequences for SP1 and ATF-CREB suggesting that these may be important for 
activation (Figure 15).  As discussed in the promoter regulation section, SP1 and ATF-
CREB are upregulated upon HCMV infection and are important in regulating HCMV 
gene expression  (83, 91, 93).  The significant increase in SEAP levels after the deletion 
of the region between -315 and -511 supports the presence of a repressor-binding site. 
This region contains 3 sites PEA3, AP2 and YY1 (Figure 15). YY1 is known to activate 
and repress transcription depending on associated factors such as location of its binding 
relative to transcription start site and post translational modifications  (112).  Some 
previous work indicates that YY1 can repress the HCMV MIEP enhancer (98), so it is 
reasonable to hypothesize that YY1 may be binding directly to the recognition sequence 
in m143 promoter or may be recruiting additional repressors to form a co-repressor 
complex to repress the m143 promoter.  HCMV attachment stimulates the production and 
activity of several cellular transcription factors  (79, 113).  When the virus is UV 
inactivated it becomes a non-infectious viral particle, which means that viral DNA is not 
capable of replication and gene expression. When it is used for treatment it can attach, 
enter and release viral structural proteins and DNA in to the cell, these events alone can 
trigger various initial signaling pathways as described in promoter regulation (79, 114).  
We have investigated if treatment with UV inactivated MCMV affected the regulation of 
the m143 promoter. Treatment with UV inactivated MCMV resulted in no detectable 
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changes in m143 promoter regulation either alone or after activation by IE1/IE3 
suggesting that viral attachment, entry and tegument proteins do not have any effect on 
m143 promoter which agrees with previous luciferase data (68).  Some immediate early 
proteins of CMV are known to regulate various viral and cellular promoters. Previously 
discussed splice variants, IE1/IE3 are the known transcriptional regulators of MCMV. 
IE1 can activate the shared promoter, the MIEP and IE3 can repress this promoter (54, 
115).  We wanted to see if these immediate early proteins have any effect on m143 
promoter’s activation, Co-transfections with a plasmid that expresses both IE1/IE3 
showed these are sufficient to activate the m143 promoter. Even though IE1 and IE3 
alone are able to activate the m143 promoter, when IE1/IE3 are present together, the 
SEAP activity levels of m143 promoter increases significantly which indicates that they 
are acting synergistically.  An explanation for this behavior could be, that IE1/IE3 form a 
complex and bind to the promoter either directly or via other transcriptional factors.  
Since there is no repression seen in co-transfections with IE1/IE3, the repression between 
-511 and -315 and -124 and +4 constructs may be coming from a viral protein other than 
IE1/IE3. No significant difference was seen with IE1/IE3 co-transfections and treated 
with UV inactivated virus, indicating that no combined effect of tegument and IE1/IE3 on 
the m143 promoter regulation. Since proteins other than immediate early proteins are 
involved in the regulation of the m143 promoter, we did MCMV infection followed by 
PFA treatment to prevent late gene synthesis and the results suggests that late proteins are 
not important in regulating the m143 promoter.  The results from UV treatment and PFA 
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treatments suggest that the repressors are viral proteins, which are not tegument or late 
proteins.  Recent studies show a viral repressor in HCMV, UL34, the UL34 gene 
expresses two forms of proteins, an early and a late.  UL34 has 14 binding sites in the 
HCMV genome and has been shown to repress at least two HCMV promoters, an 
immediate early gene (US3) and an early gene (US9) (116).  UL34 has a homologue in 
MCMV, m34, which could be binding to m143 promoter and repressing its gene 
expression (40).  Although the DNA sequence bound by UL 34 was not found in the 
m143 promoter, it is unknown if m34 binds to the same sequence.  
Identification of transcription binding factors that are involved in the regulation of 
the m143 promoter 
After we found important regulatory regions of the m143 promoter, we wanted to 
see if SP1 and TATA binding factors are involved in the regulation of m143 promoter.  
The SP1 cellular transcription factor was suspected to have an important role in the 
regulation of the m143 promoter because of the activation in the constructs with this site 
present, in addition previous work indicates that HCMV increases SP1 levels and activity 
(93).  Electrophoretic mobility shift assay was performed to examine binding of protein 
complexes to SP1 site that is present at -187 to -178 in the m143 promoter, this site was 
chosen because of the low number of consensus sites in this region.  Our gel shift results 
indicate binding with multiple protein complexes.  Proteins or complexes from nuclear 
extracts bound to the labeled SP1 oligo and at least one was specific binding because 
addition of non-specific unlabelled competitor did not inhibit the binding, if anything 
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binding was enhanced.  Faint bands of the same size were observed in the mock nuclear 
extract, which indicates that MCMV infection may be up regulating this binding or 
increasing nuclear localization of the required proteins.  The multiple bands observed in 
the gel shift could be explained the capacity of SP1 to bind to multiple cellular and viral 
proteins. Probe bound SP1 may be binding to different proteins and resulting into 
multiple specific shifted bands.  These results would be consistent with an upregulation in 
SP1 protein or activity as reported for HCMV, supporting similar mechanisms in MCMV. 
Several bands were seen with TATA oligo, which indicates the binding of proteins, but it 
is not consistent in all extracts. So no final conclusions could be drawn. 
 The results of this study indicate that multiple viral and cellular factors are 
involved in regulating the m143 promoter.  The major immediate early proteins IE1 and 
IE3 are required.  Cellular SP1 may also be important and may be upregulated. Finally, It 
appears that other viral proteins repress the m143 promoter. Identification of the 
repressive mechanisms for this essential gene could lead to new ways to control 
cytomegalovirus infection and disease. 
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APPENDIX 
 
Abbreviations 
 
Cytomegalovirus         CMV 
Human cytomegalovirus        HCMV 
Murine cytomegalovirus        MCMV 
Cytopathic effect         CPE 
Gancyclovir          GCV 
Endoplasmic reticulum        ER 
Epithelial growth factor receptor       EGFR 
Immediate-early         IE 
Early           E 
Late           L 
Hours post infection         hpi 
Major immediate early promoter       MIEP 
Phosphonoformic acid        PFA 
CCAAT displacement protein       CDP 
Open reading frames         ORFs 
Unique short          US 
Unique long          UL 
Protein kinase R         PKR 
Transcription factors         TFs 
TATA binding protein        TBP 
  
69  
Transcription factor IID        TFIID 
Extracellular-signal-regulated kinases      ERKs 
cAMP response-element-binding protein      CREB 
Necrotic factor kappa beta        NF-kβ 
Nuclear domains         ND10 
Kanamycin          Kan 
Ampicillin          Amp 
Secreted embryonic alkaline phosphatase      SEAP 
Dulbecco's modified Eagle's medium      DMEM 
Bovine calf serum         BCS 
Multiplication of infection        MOI 
Cytopathic effect         CPE 
Poly A binding protein        PABP 
Electrophoretic Mobility Shift Assay      EMSA 
Nuclear extract         NE 
Cytoplasmic extract         CE 
Bovine serum albumin        BSA 
Tris borate EDTA buffer        TBE 
Transcription element search system       TESS  
 
 
 
 
